Others NUROKIND LC TABLET is not recommended for use if you have: Lebers disease (hereditary eye disease) Before taking NUROKIND LC TABLET inform your doctor if you have: polycythaemia vera (a type of blood cancer) folic acid deficiency megaloblastic anaemia (abnormal large red blood cells) undiagnosed anaemias, pernicious anaemias (decrease in red blood cells due to vitamin B12 deficiency) malabsorption syndrome (difficulty absorbing nutrients from diet) history of gastrectomy (removal of part of the stomach) history of seizures (fits) Interactions A
After normalizing the target mRNA expression to ACTB , the normalized CT method was used to calculate the fold change in gene expression 47,48
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
Citrus fruits : High in vitamin C, which aids collagen formation
Potential concerns include the peptide's angiogenic properties
HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]